Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is thought to exert its effects by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA).
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Adult Dosing
* **LGS:** The recommended starting dose is 5 mg twice daily.
* The dose should be titrated upward by 5 mg to 10 mg every week based on clinical response and tolerability.
* The maximum recommended dose is 20 mg twice daily.
## Pediatric Dosing
* **LGS (2 to less than 10 years of age):**
* Starting dose: 2.5 mg twice daily.
* Titration: Increase by 2.5 mg to 5 mg every week based on clinical response and tolerability.
* Maximum recommended dose: 10 mg twice daily.
* **LGS (10 years of age and older):** Dosing is the same as for adults.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are provided in the prescribing information, but reduced doses may be necessary due to decreased metabolism.
* **Renal Impairment:** Use with caution. No specific dose adjustments are provided in the prescribing information.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, fatigue, aggression, irritability, pyrexia, respiratory tract infections, pneumonia.
* **Serious:** Suicidal behavior and ideation, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence and withdrawal symptoms, paradoxical reactions (increased seizure frequency/intensity, excitation).
## Key Drug Interactions
* **CYP2C19 Inhibitors (e.g., fluconazole, omeprazole):** May increase clobazam concentrations. Consider dose reduction of clobazam.
* **CYP2C19 Inducers (e.g., rifampin, carbamazepine):** May decrease clobazam concentrations. Consider dose increase of clobazam.
* **CNS Depressants (e.g., opioids, alcohol, other sedatives):** Additive CNS depressant effects may occur, increasing the risk of sedation, respiratory depression, and potentially fatal outcomes.
## Monitoring
* Monitor for signs of suicidal behavior and ideation.
* Monitor for signs of severe skin reactions.
* Monitor for drowsiness and sedation, especially when co-administered with other CNS depressants.
* Monitor for effectiveness in seizure control.
* Monitor for signs of withdrawal upon discontinuation.
## Clinical Pearls
* Clobazam should be initiated by a physician experienced in the treatment of epilepsy.
* Gradual withdrawal is recommended to avoid withdrawal symptoms.
* Due to its long half-life, clobazam can accumulate with chronic use.
* Risk of serious skin reactions is higher with concomitant use of certain antiepileptic drugs.
***
**Disclaimer:** This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information and current clinical guidelines. Dosing and recommendations may vary based on individual patient factors and local protocols. Always verify current prescribing information before making clinical decisions.
